{"nctId":"NCT00358917","briefTitle":"Study of Lopinavir/Ritonavir Tablets Comparing Once-Daily Versus Twice-Daily Administration When Coadministered With Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Antiretroviral-Experienced Human Immunodeficiency Virus Type 1 Infected Subjects","startDateStruct":{"date":"2006-08"},"conditions":["Human Immunodeficiency Virus Infections"],"count":599,"armGroups":[{"label":"LPV/r 800/200 mg QD Tablet","type":"EXPERIMENTAL","interventionNames":["Drug: lopinavir/ritonavir (LPV/r) tablet with nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs)"]},{"label":"LPV/r 400/100 mg BID Tablet","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: lopinavir/ritonavir (LPV/r) tablet with nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs)"]}],"interventions":[{"name":"lopinavir/ritonavir (LPV/r) tablet with nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs)","otherNames":["ABT-378","lopinavir/ritonavir","Kaletra"]},{"name":"lopinavir/ritonavir (LPV/r) tablet with nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs)","otherNames":["ABT-378","lopinavir/ritonavir","Kaletra"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects were human immunodeficiency virus type 1 (HIV-1) positive, antiretroviral-experienced adults at least 18 years of age currently receiving an antiretroviral regimen which had not changed for at least 12 weeks.\n* Subjects had plasma HIV-1 ribonucleic acid (RNA) levels \\> 1,000 copies/mL at screening and were not acutely ill.\n* Subject was currently failing his/her antiretroviral regimen with the most recent 2 consecutive prestudy plasma HIV-1 RNA levels \\> 400 copies/mL with the most recent being \\> 1000 copies/mL, and in the investigator's opinion, should change therapy\n* Female subjects were nonpregnant and nonlactating.\n\nExclusion Criteria:\n\n* Subjects were excluded if screening laboratory analyses showed hemoglobin \\<= 8.0 grams per deciliter.\n* Subjects were excluded if screening laboratory analyses showed absolute neutrophil count \\<= 750 cells/microliter.\n* Subjects were excluded if screening laboratory analyses showed platelet count \\<= 50,000 per cubic millimeter.\n* Subjects were excluded if screening laboratory analyses showed alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\>= 5.0 x upper limit of normal (ULN).","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Responding at Week 48 Based on the Food and Drug Administration (FDA) Time to Loss of Virologic Response (TLOVR) Algorithm","description":"A participant was classified as a responder at the first of 2 consecutive human immunodeficiency virus type 1 (HIV-1) ribonucleic acid (RNA) levels \\<50 copies/mL. The participant continued to be a responder until 2 consecutive values \\>=50 copies/mL were reached, until the final value if that value was \\>=50 copies/mL, or until discontinuation or death.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"55.3","spread":null},{"groupId":"OG001","value":"51.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Plasma Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) Levels < 50 Copies/Milliliter (mL) at Week 48","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"76.0","spread":null},{"groupId":"OG001","value":"72.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline to Week 48 in Cluster of Differentiation 4 Single-Positive Thymocyte (CD4+ T) Cell Counts","description":null,"paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"135.3","spread":"9.03"},{"groupId":"OG001","value":"121.5","spread":"9.08"}]}]}]},{"type":"SECONDARY","title":"Virologic Response (HIV-1 RNA <50 Copies/mL) at Week 48 for Participants With 0-2 Protease Inhibitor Substitutions at Baseline Associated With Reduced Response to Lopinavir/Ritonavir","description":"Substitutions considered in the analysis were L10F/I/R/V, K20M/N/R, L24I, L33F, M36I, I47V, G48V, I54L/T/V, V82A/C/F/S/T, and I84V as defined in the proposed United States Package Insert.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"65.5","spread":null},{"groupId":"OG001","value":"61.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With New Primary Protease Mutations at Week 48","description":"Emergence of new primary protease inhibitor mutations (i.e., mutations at codons 30, 32, 48, 50, 82, 84, and 90 that were not present at baseline).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.0","spread":null},{"groupId":"OG001","value":"15.6","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":27,"n":300},"commonTop":["Diarrhoea","Nausea","Vomiting","Upper respiratory tract infection","Headache"]}}}